News
-
Map for Clinical Trials in the EU
The European Medicines Agency (EMA) has launched a new map to provide comprehensive, real-time information on clinical trials taking place in the EU.
-
Romania’s Pioneering Law: Establishing the Right to Personalised Medicine
This best practice example discusses Romania’s groundbreaking law, the first in the world to recognise the right of citizens and patients to personalised medicine. Initiated following the EU Council’s 2015 personalised medicine policy, the law is the result of a multi-sectoral collaboration led by the Centre for Innovation in Medicine in Romania.
-
EP PerMed Guidelines for Data Reusability for Personalised Pedicine Researchers published
The EP PerMed Guidelines for Data Reusability aim to guide personalised medicine researchers and other stakeholders by outlining key principles of data reusability and its associated challenges.
-
EP PerMed Round Table – 2nd Edition: Spain and Portugal
The 2nd edition of the EP PerMed Round Table will take place on 31 March 2025. The event will focus on Spain and Portugal, bringing together key stakeholders to address challenges, share success stories and promote concrete actions in personalised medicine. The discussion will be live-streamed to ensure access to this critical debate.
EP PerMed JTC 2025
#PGxPM2025
With its second Joint Transnational Call (JTC), EP PerMed aims to fund human health research on pharmacogenomic strategies for personalised medicine approaches. The deadline for submission of pre-proposals was 18 February 2025. Funding decisions are expected to be communicated in October 2025.
EP PerMed Summer School
Mission & Objectives
Governance & Boards
The European Partnership for Personalised Medicine gathers together around 60 partners from 25 countries. The Consortium is managed by a so-called Coordination Unit (CU) and General Assembly (GeA). The day-to-day business, planning and implementation of activities is realized through five Work Packages. The EP PerMed overarching Advisory Bodies are ICPerMed, an Advisory Board and a Stakeholder Forum.